Aredo et al. explored the impact of KRAS mutation and co-mutations in the prognosis of NSCLC patients and found that KRASG12D mutation was significantly associated with OS in multivariate analysis, and STK11 co-mutation was also significantly associated with OS [18]. Here, KRAS is linked to non-small cell lung carcinoma.